Fenofibrate use and diabetic retinopathy progression in patients with type 2 diabetes: a propensity-matched cohort study
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, N. | - |
dc.contributor.author | Kim, J. | - |
dc.contributor.author | Kim, K. | - |
dc.contributor.author | Bae, J. | - |
dc.contributor.author | Kim, K. | - |
dc.contributor.author | Kim, S. | - |
dc.date.accessioned | 2022-09-06T02:40:10Z | - |
dc.date.available | 2022-09-06T02:40:10Z | - |
dc.date.issued | 20220921 | - |
dc.identifier.issn | 0012-186X | - |
dc.identifier.issn | 1432-0428 | - |
dc.identifier.uri | https://scholarworks.korea.ac.kr/kumedicine/handle/2021.sw.kumedicine/61436 | - |
dc.description.abstract | Background and aims: To determine the association between fenofibrate use and diabetic retinopathy progression in patients with type 2 diabetes (T2D) and metabolic syndrome undergoing statin therapy in a real-world database. Materials and methods: In this propensity-matched cohort study, patients with T2D and metabolic syndrome (≥ 30 years) receiving statin therapy were matched 1:2 by propensity score into the statin plus fenofibrate group (n=23,692) and statin-only group (n=46,223). The primary outcome was a composite of diabetic retinopathy progression including vitreous hemorrhage, vitrectomy, laser photocoagulation, intravitreous injection therapy and retinal detachment. Results: For the primary outcome, the incidence rate per 1,000 person year was 14.25 in the statin-only group and 12.65 in the statin plus fenofibrate group. The risk of the primary outcome was significantly lower (hazard ratio [HR], 0.89; 95% confidence interval [CI], 0.83 to 0.96; p=0.001) in the statin plus fenofibrate group than in the statin-only group. Patients with retinopathy at baseline showed marked benefits of fenofibrate treatment (HR, 0.86; 95% CI, 0.78 to 0.94; p=0.001). In addition, the statin plus fenofibrate group exhibited significantly lower risks of vitreous hemorrhage (HR, 0.87; 95% CI, 0.78 to 0.96; p=0.008), laser photocoagulation (HR, 0.89; 95% CI, 0.81 to 0.98, p=0.022) and intravitreous injection therapy (HR, 0.78; 95% CI, 0.66 to 0.92; p=0.003) than those in the statin-only group. There was no significant interaction between the different characteristics at baseline and the treatment effect. Conclusion: In this propensity-weighted cohort study, the addition of fenofibrate to statins was associated with significantly lower risk of diabetic retinopathy progression than statin therapy alone in patients with T2D and metabolic syndrome. | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.title | Fenofibrate use and diabetic retinopathy progression in patients with type 2 diabetes: a propensity-matched cohort study | - |
dc.type | Conference | - |
dc.identifier.doi | 10.1007/s00125-022-05755-w | - |
dc.citation.title | Diabetologia | - |
dc.citation.startPage | S66 | - |
dc.citation.endPage | S66 | - |
dc.citation.conferenceName | 58th EASD Annual Meeting | - |
dc.citation.conferencePlace | 스웨덴 | - |
dc.citation.conferencePlace | Stockholm, Sweden | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
73, Goryeodae-ro, Seongbuk-gu, Seoul, Republic of Korea (02841)82-2-2286-1265
COPYRIGHT 2020 KOREA UNIVERSITY MEDICAL LIBRARY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.